Page last updated: 2024-08-24

lamivudine and foscarnet

lamivudine has been researched along with foscarnet in 26 studies

Research

Studies (26)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	6 (23.08)	18.2507
2000's	10 (38.46)	29.6817
2010's	10 (38.46)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cha, SH; Endou, H; Kanai, Y; Kimura, M; Sekine, T; Tsuda, M; Wada, S	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Lombardo, F; Obach, RS; Waters, NJ	1
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Campillo, NE; Guerra, A; Páez, JA	1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV	1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ	1
Ekins, S; Williams, AJ; Xu, JJ	1
Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A	1
Bi, CW; Du, NN; Gao, LM; Han, YX; Jiang, JD; Li, X; Li, YH; Peng, ZG; Shan, YQ; Song, DQ; Wang, YP; Zhang, T	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Berthillon, P; Camplo, M; Charvet, AS; Chermann, JC; Faury, P; Graciet, JC; Hantz, O; Mourier, N; Trépo, C; Turin, F	1
Camplo, M; Charvet, AS; Chermann, JC; Faury, P; Graciet, JC; Kraus, JL; Mourier, N	1
Alaeus, A; Albert, J; Cox, S; Palmer, S	1
Keating, MR	1
Durand, H; Gisselbrecht, M; Haas, C; Lowenstein, W; Marteau, P; Roudière, L	1
Chen, HS; Chen, XH; Han, YX; Jiang, JD; Li, JN; Li, YH; Wang, YL; Wu, YW; Xue, R; You, XF; Zhao, LX; Zhao, W; Zhou, ZX	1
Clavel, F; Dam, E; Gerstoft, J; Joergensen, LB; Laursen, AL; Mathiesen, S; Roge, B	1
Kisic, M; Martínez, MA; Martinez-Picado, J; Mendieta, J; Menéndez-Arias, L; Parera, M; Puertas, MC	1
Razonable, RR	1
Agut, H; Caumes, E; Challine, D; Deback, C; Lascaux, AS; Lévy, Y; Melica, G	1
Liu, J; Liu, Q; Tian, C; Wang, J; Wang, X; Zhang, L; Zhang, Y; Zhang, Z; Zhao, J	1

Reviews

3 review(s) available for lamivudine and foscarnet

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Antiviral agents for non-human immunodeficiency virus infections. Mayo Clinic proceedings, 1999, Volume: 74, Issue:12 Topics: 2-Aminopurine; Acetamides; Acyclovir; Amantadine; Antiviral Agents; Cidofovir; Cytosine; Drug Resistance, Microbial; Drugs, Investigational; Enzyme Inhibitors; Famciclovir; Foscarnet; Ganciclovir; Guanidines; Guanine; Humans; Interferons; Lamivudine; Neuraminidase; Organophosphonates; Organophosphorus Compounds; Oseltamivir; Pyrans; Ribavirin; Sialic Acids; Valacyclovir; Valine; Virus Diseases; Zanamivir	1999
Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clinic proceedings, 2011, Volume: 86, Issue:10 Topics: Acyclovir; Adenine; Amantadine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Foscarnet; Ganciclovir; Guanine; Hepatitis; Hepatitis B, Chronic; Hepatitis C; Herpesviridae Infections; HIV Infections; Humans; Influenza, Human; Interferons; Lamivudine; Nucleosides; Oligopeptides; Organophosphonates; Oseltamivir; Proline; Protease Inhibitors; Pyrimidinones; Ribavirin; Telbivudine; Thymidine; Valacyclovir; Valganciclovir; Valine; Virus Replication; Zanamivir	2011

Trials

1 trial(s) available for lamivudine and foscarnet

Article	Year
Antiviral therapeutic efficacy of foscarnet in hepatitis B virus infection. Antiviral research, 2005, Volume: 68, Issue:3 Topics: Adult; Aged; Antiviral Agents; Cell Culture Techniques; Drug Therapy, Combination; Female; Foscarnet; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Treatment Outcome	2005

Other Studies

22 other study(ies) available for lamivudine and foscarnet

Article	Year
Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs. The Journal of pharmacology and experimental therapeutics, 2000, Volume: 294, Issue:3 Topics: Acyclovir; Animals; Anion Transport Proteins; Antiviral Agents; Carrier Proteins; Didanosine; In Vitro Techniques; Lamivudine; Oocytes; Rats; Stavudine; Transfection; Trifluridine; Xenopus laevis; Zalcitabine; Zidovudine	2000
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. Bioorganic & medicinal chemistry, 2009, Jan-15, Volume: 17, Issue:2 Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship	2009
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
Neural computational prediction of oral drug absorption based on CODES 2D descriptors. European journal of medicinal chemistry, 2010, Volume: 45, Issue:3 Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical	2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3 Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations	2010
Developing structure-activity relationships for the prediction of hepatotoxicity. Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
Prediction of drug intestinal absorption by new linear and non-linear QSPR. European journal of medicinal chemistry, 2011, Volume: 46, Issue:1 Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics	2011
Design and synthesis of oxymatrine analogues overcoming drug resistance in hepatitis B virus through targeting host heat stress cognate 70. Journal of medicinal chemistry, 2011, Feb-10, Volume: 54, Issue:3 Topics: Administration, Oral; Alkaloids; Animals; Antiviral Agents; Down-Regulation; Drug Design; Drug Resistance, Viral; Hep G2 Cells; Hepatitis B virus; HSC70 Heat-Shock Proteins; Humans; Lamivudine; Lethal Dose 50; Mice; Molecular Conformation; Quinolizines; RNA, Messenger; Structure-Activity Relationship	2011
Drugs for AIDS and associated infections. The Medical letter on drugs and therapeutics, 1995, Oct-13, Volume: 37, Issue:959 Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Antiprotozoal Agents; Antiviral Agents; Atovaquone; Candidiasis, Oral; Clindamycin; Clotrimazole; Cryptosporidiosis; Cytomegalovirus Infections; Dapsone; Didanosine; Drug Combinations; Drug Therapy, Combination; Fluconazole; Flucytosine; Folic Acid Antagonists; Foscarnet; Glucuronates; Herpes Simplex; Herpes Zoster; Humans; Isoniazid; Itraconazole; Ketoconazole; Lamivudine; Mycobacterium avium-intracellulare Infection; Naphthoquinones; Nystatin; Pentamidine; Pneumocystis Infections; Pneumonia, Pneumocystis; Prednisone; Primaquine; Reverse Transcriptase Inhibitors; Stavudine; Syphilis; Toxoplasmosis; Trimetrexate; Tuberculosis; Zalcitabine; Zidovudine	1995
Synthesis and antiviral activity of new carbonylphosphonate 2',3'-dideoxy-3'-thiacytidine conjugates. Antiviral research, 1994, Volume: 25, Issue:2 Topics: Animals; Antiviral Agents; Cells, Cultured; Cytopathogenic Effect, Viral; Drug Evaluation, Preclinical; Ducks; Foscarnet; Giant Cells; Hepatitis B Virus, Duck; HIV-1; Humans; Lamivudine; Liver; Magnetic Resonance Spectroscopy; Mass Spectrometry; Molecular Structure; Structure-Activity Relationship; Thionucleosides; Zalcitabine	1994
Inhibition of human immunodeficiency virus type 1 replication by phosphonoformate- and phosphonoacetate-2',3'-dideoxy-3'-thiacytidine conjugates. Journal of medicinal chemistry, 1994, Jul-08, Volume: 37, Issue:14 Topics: Antiviral Agents; Foscarnet; HIV-1; Lamivudine; Phosphonoacetic Acid; Prodrugs; Structure-Activity Relationship; Virus Replication; Zalcitabine	1994
Drugs for non-HIV viral infections. The Medical letter on drugs and therapeutics, 1997, Aug-01, Volume: 39, Issue:1006 Topics: 2-Aminopurine; Abnormalities, Drug-Induced; Acyclovir; Amantadine; Antiviral Agents; Cidofovir; Contraindications; Cytosine; Drug Resistance, Microbial; Eye Infections, Viral; Famciclovir; Foscarnet; Ganciclovir; Guanine; Humans; Interferon-alpha; Kidney Diseases; Lamivudine; Organophosphonates; Organophosphorus Compounds; Prodrugs; Ribavirin; Rimantadine; Trifluridine; Valacyclovir; Valine; Virus Diseases	1997
Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates. AIDS research and human retroviruses, 1998, Jan-20, Volume: 14, Issue:2 Topics: Anti-HIV Agents; Cell Line, Transformed; Cells, Cultured; Didanosine; Foscarnet; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Zidovudine	1998
[Severe cytomegalovirus enteritis in AIDS. Favorable outcome of medical treatment]. Presse medicale (Paris, France : 1983), 2000, Mar-25, Volume: 29, Issue:11 Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Celiac Disease; Cytomegalovirus Infections; Foscarnet; Ganciclovir; HIV Protease Inhibitors; Humans; Lamivudine; Male; Nelfinavir; Parenteral Nutrition; Pentamidine; Protein-Losing Enteropathies; Reverse Transcriptase Inhibitors; Stavudine; Time Factors; Treatment Outcome	2000
Drugs for non-HIV viral infections. The Medical letter on drugs and therapeutics, 2002, Feb-04, Volume: 44, Issue:1123 Topics: 2-Aminopurine; Acyclovir; Administration, Oral; Administration, Topical; Amantadine; Animals; Antiviral Agents; Cidofovir; Cytosine; Famciclovir; Foscarnet; Guanine; Herpesviridae Infections; Humans; Influenza, Human; Injections, Intravenous; Lamivudine; Organophosphonates; Organophosphorus Compounds; Rats; Ribavirin; Rimantadine; Thionucleotides; Trifluridine; Valacyclovir; Valine	2002
Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1. Antiviral therapy, 2007, Volume: 12, Issue:3 Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Multiple, Viral; Evolution, Molecular; Foscarnet; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Point Mutation; Reverse Transcriptase Inhibitors; Species Specificity; Thymidine; Time Factors; Zidovudine	2007
Mechanistic basis of zidovudine hypersusceptibility and lamivudine resistance conferred by the deletion of codon 69 in the HIV-1 reverse transcriptase coding region. Journal of molecular biology, 2008, Oct-03, Volume: 382, Issue:2 Topics: Amino Acid Sequence; Anti-HIV Agents; Codon; Crystallography, X-Ray; Deoxycytosine Nucleotides; DNA, Viral; Drug Resistance, Multiple, Viral; Foscarnet; HIV Infections; HIV Reverse Transcriptase; Humans; Lamivudine; Models, Molecular; Molecular Sequence Data; Mutation; Nucleic Acid Conformation; Protein Conformation; Reverse Transcriptase Inhibitors; Sequence Alignment; Sequence Deletion; Zidovudine	2008
Successful treatment of aciclovir and foscarnet resistant Herpes simplex virus lesions with topical imiquimod in patients infected with human immunodeficiency virus type 1. Journal of medical virology, 2012, Volume: 84, Issue:2 Topics: Acyclovir; Administration, Topical; Adult; Aminoquinolines; Antiviral Agents; Drug Resistance, Viral; Foscarnet; Herpes Simplex; HIV Infections; HIV-1; Humans; Imiquimod; Lamivudine; Male; Middle Aged; Nelfinavir; Simplexvirus; Zidovudine	2012
2-Arylthio-5-iodo pyrimidine derivatives as non-nucleoside HBV polymerase inhibitors. Bioorganic & medicinal chemistry, 2018, 05-01, Volume: 26, Issue:8 Topics: Animals; Antiviral Agents; Dose-Response Relationship, Drug; Ducks; Gene Products, pol; Hep G2 Cells; Hepatitis B virus; Humans; Liver; Microbial Sensitivity Tests; Molecular Structure; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Sulfhydryl Compounds	2018